新型冠状病毒疫苗研发策略综述

doi:10.12183/j.scjpm.2021.1003

摘要/Abstract

摘要： 席卷全球的新型冠状病毒肺炎疫情给人类的生命健康安全带来巨大威胁,疫苗是防控疫情最为经济有效的手段。疫情暴发后,全球医药企业与科研机构快速启动了新型冠状病毒疫苗的研发,疫苗设计策略主要包括灭活疫苗、病毒载体疫苗、亚单位疫苗、减毒活疫苗和核酸疫苗等,经历1年的多方努力,目前已有多款疫苗相继公布Ⅲ期临床数据并获得紧急使用权限甚至被批准上市。本文将重点介绍新型冠状病毒疫苗免疫原靶标的选择,梳理当前不同类型疫苗的研究进展,并阐述新冠疫苗所面临的主要问题,以期为疫苗后续的改进提供有益借鉴。

关键词: 新冠疫苗, S蛋白, 疫苗研发策略, 研究进展

中图分类号:

R186

马勇, 胡芸琦, 翟燕镅, 陈耀庆. 新型冠状病毒疫苗研发策略综述[J]. 华南预防医学, 2021, 47(8): 1003-1011.

参考文献

[1] Anderson RM, Vegvari C, Truscott J, et al.Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination[J].Lancet,2020, 396(10263):1614-1616.
[2] Dai L, Gao GF.Viral targets for vaccines against COVID-19[J].Nat Rev Immunol,2020,21(2):73-82.
[3] Xu XT, Chen P, Wang JF, et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J].Sci China Life Sci,2020,63(3):457-460.
[4] Gavor E, Choong YK, Er SY, et al.Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions[J].Trends Immunol,2020,41(11):1006-1022.
[5] Wu Y, Wang FR, Shen CG, et al.A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2[J].Science,2020, 368(6496):1274-1278.
[6] Cao YL, Su B, Guo XH, et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells[J].Cell,2020,182(1):73-84.
[7] Shi R, Shan C, Duan XM, et al.A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2[J].Nature 2020,584(7819):120-124.
[8] Ju B, Zhang Q, Ge JW, et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection[J].Nature,2020,584(7819):115-119.
[9] Wan JK, Xing SH, Ding LF, et al.Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection[J].Cell Rep,2020,32(3):107918.
[10] Wec AZ, Wrapp D, Herbert AS, et al.Broad neutralization of SARS-related viruses by human monoclonal antibodies[J].Science,2020,369(6504):731-736.
[11] Hansen J, Baum A, Pascal KE, et al.Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail[J]. Science,2020,369(6506):1010-1014.
[12] Grifoni A, Weiskopf D, Ramirez SI, et al.Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals[J].Cell,2020,181(7):1489-1501.
[13] Pallesen J, Wang NS, Corbett KS, et al.Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen[J].P Natl Acad Sci USA,2017,114(35):E7348-E7357.
[14] Corbett KS, Flynn B, Foulds KE, et al.Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates[J].New Engl J Med,2020,383(16):1544-1555.
[15] Walsh EE, Frenck R, Falsey AR, et al.RNA-Based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study[J].medRxiv,2020.
[16] Tostanoski LH, Wegmann F, Martinot AJ, et al.Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters[J].Nat Med,2020,26(11):1694-1700.
[17] Bangaru S, Ozorowski G, Turner HL, et al.Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate[J].Science,2020, 370(6520):1089-1094.
[18] Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses[J].NPJ Vaccines,2020,5:91.
[19] Richmond P, Hatchuel L, Dong M, et al.Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial[J]. Lancet,2021,397(10275):682-694.
[20] Chi XY, Yan RH, Zhang J, et al.A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2[J].Science,2020, 369(6504):650-655.
[21] Yang J, Wang W, Chen Z, et al.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J].Nature,2020,586(7830):572-577.
[22] Zhou MH, Xu DP, Li XJ, et al.Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes[J].J Immunol,2006,177(4):2138-2145.
[23] Zhang NN, Li XF, Deng YQ, et al.A Thermostable mRNA Vaccine against COVID-19[J].Cell,2020,182(5):1271-1283.
[24] Walls AC, Fiala B, Schafer A, et al.Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2[J].Cell,2020,183(5):1367-1382.
[25] Sahin U, Muik A, Derhovanessian E, et al.COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses[J].Nature,2020,586(7830):594-599.
[26] Sun J, Zhuang Z, Zheng J, et al.Generation of a broadly useful model for COVID-19 pathogenesis,vaccination, and treatment[J].Cell,2020,182(3):734-743.
[27] Yasui F, Kai C, Kitabatake M, et al.Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV[J].J Immunol,2008,181(9):6337-6348.
[28] Wang H, Zhang YT, Huang BY, et al.Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2[J]. Cell,2020,182(3):713-721.
[29] Polack FP, Thomas SJ, Kitchin N, et al.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J].N Engl J Med,2020,383(27):2603-2615.
[30] Xia S, Duan K, Zhang Y, et al.Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials[J].JAMA,2020,324(10):951-960.
[31] Gao Q, Bao LL, Mao HY, et al.Development of an inactivated vaccine candidate for SARS-CoV-2[J].Science 2020,369(6499):77-81.
[32] Logunov DY, Dolzhikova IV, Zubkova OV, et al.Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia[J]. Lancet,2020,396(10255):887-897.
[33] Baden LR, El Sahly HM, Essink B, et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine[J].N Engl J Med,2020,384(5):403-416.
[34] Silva-Cayetano A, Foster WS, Innocentin S, et al.A Booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice[J].Med (N Y),2021,2(3):243-262.
[35] Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial[J].Lancet Infect Dis,2021,S1473-3099(20):30942-30947.
[36] Zhang Y, Zeng G, Pan H, et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis,2021,21(2):181-192.
[37] Balakrishnan VS.The arrival of sputnik V[J].Lancet Infect Dis,2020,20(10):1128.
[38] Voysey M, Clemens SAC, Madhi SA, et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK[J]. Lancet,2021,397(10269):99-111.
[39] Mercado NB, Zahn R, Wegmann F, et al.Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques[J].Nature,2020,586(7830):583-588.
[40] Wang P, Zheng M, Lau SY, et al.Generation of DelNS1 influenza viruses: A strategy for optimizing live attenuated influenza vaccines[J].mBio,2019,10(5):e02180-19.
[41] Dai L, Zheng T, Xu K, et al.A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS[J].Cell,2020,182(3):722-33 e11.
[42] Keech C, Albert G, Cho I, et al.Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J].N Engl J Med,2020,383(24):2320-2332.
[43] Guebre-Xabier M, Patel N, Tian JH, et al.NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge[J]. Vaccine,2020,38(50):7892-7896.
[44] Smith TRF, Patel A, Ramos S, et al.Immunogenicity of a DNA vaccine candidate for COVID-19[J].Nat Commun,2020,11(1):2601.
[45] Zhang NN, Li XF, Deng YQ, et al.A thermostable mRNA vaccine against COVID-19[J].Cell,2020,182(5):1271-83 e16.
[46] Zhao J, Zhao S, Ou J, et al.COVID-19: Coronavirus vaccine development updates[J].Front Immunol,2020,11:602256.
[47] Li Q, Wu J, Nie J, et al.The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity[J].Cell,2020,182(5):1284-1294 .
[48] Guruprasad L.Human SARS CoV-2 spike protein mutations[J].Proteins,2021,89(5):59-576.
[49] Thomson EC, Rosen LE, Shepherd JG, et al.Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity[J]. Cell,2021,184(5):1171-1187.
[50] Lee WS, Wheatley AK, Kent SJ, et al.Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies[J].Nat Microbiol,2020,5(10):1185-1191.
[51] Rey FA, Stiasny K, Vaney MC, et al.The bright and the dark side of human antibody responses to flaviviruses: Lessons for vaccine design[J].Embo Rep,2018,19(2):206-224.
[52] 国家卫生健康委办公厅,国家中医药管理局办公室.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL].(2020-03-04)[ 2021-03-01]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml?security_session_verify=4aec1a086c7cda51ef74e57abb58d3de.
[53] Zhang Y, Zeng G, Pan H, et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis,2021,21(2):181-192.
[54] Xia S, Zhang Y, Wang Y, et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial[J].Lancet Infect Dis,2021,21(1):39-51.
[55] Che Y, Liu X, Pu Y, et al. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults[J]. Clin Infect Dis,2020, 9:ciaa1703.
[56] Mohandas S, Yadav PD, Shete-Aich A, et al.Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model[J].iScience,2021,24(2):102054.
[57] van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques[J].Nature,2020,586(7830):578-582.
[58] Voysey M, Clemens SAC, Madhi SA, et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK[J]. Lancet,2021,397(10269):99-111.
[59] Zhu FC, Guan XH, Li YH, et al.Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet,2020,396(10249):479-488.
[60] Zhu FC, Li YH, Guan XH, et al.Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial[J].Lancet,2020, 395(10240):1845-1854.
[61] Corbett KS, Flynn B, Foulds KE, et al.Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates[J].N Engl J Med,2020,383(16):1544-1555.
[62] Anderson EJ, Rouphael NG, Widge AT, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults[J].N Engl J Med,2020,383(25):2427-2438.
[63] Mulligan MJ, Lyke KE, Kitchin N, et al.Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults[J].Nature,2020,586(7830):589-593.
[64] McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice[J].Nat Commun,2020,11(1):3523.